Polycythemia vera (PV) is a blood cancer that begins in the marrow of your bones, the soft center where new blood cells grow. It causes your marrow to make too many red blood cells so your blood ...

Although polycythemia vera management remains focused on reducing the risk of thrombotic events, there is growing recognition ...

A consistently high haemoglobin level, medically known as polycythemia, can lead to serious health issues if not managed.

In patients with renal insufficiency associated with increased hemoglobin levels and polycythemia, the possibilities of recombinant erythropoietin overdosing and disorders such as neoplasms and ...

Polycythemia vera is a slow growing blood cancer that happens in your bone marrow, the spongy tissue inside bones. It's usually caused by a gene mutation. Your bone marrow makes red blood cells ...

Among patients with polycythemia vera, the treatment pairing of Jakafi and Pegasys shows benefits with acceptable toxicity, ...

The once-daily, oral treatment is indicated for use in patients with intermediate or high-risk primary MF, post-polycythemia ...

Polycythemia vera and essential thrombocythemia are the most common chronic myeloproliferative neoplasms; their molecular basis has been appreciated only recently and is briefly discussed in this ...

First Amendment: Congress shall make no law respecting an establishment of religion, or prohibiting the free exercise thereof; or abridging the freedom of speech, or of the press; or the right of the ...

Ruxolitinib improves hematocrit control and treatment response in polycythemia vera compared to best available therapy. Patients on ruxolitinib show better Myeloproliferative Neoplasms-Symptom ...

Ojjaara (momelotinib) is the only approved treatment for newly diagnosed and previously treated myelofibrosis patients i who ...